Stock 2269 WUXI BIOLOGICS (CAYMAN) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:06 2024-04-30 am EDT 		5-day change 1st Jan Change
13.74 HKD -1.58% Intraday chart for WuXi Biologics (Cayman) Inc. +7.34% -53.58%
12:02pm Pacific Assets Trust cautiously optimistic after outpacing benchmark AN
Apr. 01 Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 114,126 353,422 318,544 223,341 113,607 53,754 - -
Enterprise Value (EV) 1 109,822 348,931 312,303 219,728 108,159 46,746 45,689 43,294
P/E ratio 116 x 216 x 97.9 x 52.3 x 34.9 x 14.3 x 11.2 x 10.1 x
Yield - - - - - - - -
Capitalization / Revenue 28.6 x 63 x 31 x 14.6 x 6.67 x 2.94 x 2.44 x 2.2 x
EV / Revenue 27.6 x 62.2 x 30.4 x 14.4 x 6.35 x 2.56 x 2.07 x 1.77 x
EV / EBITDA 65.7 x 142 x 68 x 32 x 15.5 x 7.29 x 5.79 x 5.07 x
EV / FCF -54.8 x -83.5 x -101 x -673 x - 274 x 20.1 x 21.2 x
FCF Yield -1.82% -1.2% -0.99% -0.15% - 0.36% 4.98% 4.73%
Price to Book 8.93 x 17.2 x 10.3 x 6.37 x 2.9 x 1.21 x 1.07 x 0.98 x
Nbr of stocks (in thousands) 3,883,578 4,084,763 4,224,123 4,225,262 4,222,732 4,162,831 - -
Reference price 2 29.39 86.52 75.41 52.86 26.90 12.91 12.91 12.91
Announcement Date 3/26/20 3/23/21 3/22/22 3/22/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,984 5,612 10,290 15,269 17,034 18,280 22,036 24,399
EBITDA 1 1,671 2,464 4,590 6,857 6,993 6,413 7,892 8,546
EBIT 1 1,156 2,008 3,327 4,609 4,253 4,904 6,125 6,880
Operating Margin 29.02% 35.79% 32.33% 30.18% 24.97% 26.83% 27.79% 28.2%
Earnings before Tax (EBT) 1 1,127 1,966 3,993 5,358 4,174 4,749 6,023 6,655
Net income 1 1,010 1,689 3,388 4,420 3,400 3,919 4,987 5,503
Net margin 25.36% 30.09% 32.93% 28.95% 19.96% 21.44% 22.63% 22.56%
EPS 2 0.2533 0.4000 0.7700 1.010 0.7700 0.9044 1.154 1.281
Free Cash Flow 1 -2,003 -4,178 -3,106 -326.7 - 170.5 2,276 2,046
FCF margin -50.27% -74.44% -30.19% -2.14% - 0.93% 10.33% 8.38%
FCF Conversion (EBITDA) - - - - - 2.66% 28.83% 23.94%
FCF Conversion (Net income) - - - - - 4.35% 45.63% 37.17%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/26/20 3/23/21 3/22/22 3/22/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 1,944 3,668 4,407 5,883 7,206 8,062 8,492 8,542 8,016 10,047
EBITDA - - - - - - - - - -
EBIT 1 - - 1,773 1,553 2,484 2,054 2,434 1,819 2,108 2,583
Operating Margin - - 40.24% 26.4% 34.47% 25.47% 28.66% 21.29% 26.3% 25.71%
Earnings before Tax (EBT) - 1,261 - - - 2,428 2,529 1,645 - -
Net income - 952.8 - 1,546 - 1,885 2,267 1,133 - -
Net margin - 25.97% - 26.28% - 23.38% 26.69% 13.26% - -
EPS - - - - - - 0.5200 - - -
Dividend per Share - - - - - - - - - -
Announcement Date 9/21/20 3/23/21 8/23/21 3/22/22 8/17/22 3/22/23 8/23/23 3/26/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 4,304 4,491 6,241 3,612 5,448 7,008 8,065 10,460
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -2,003 -4,178 -3,106 -327 - 171 2,276 2,046
ROE (net income / shareholders' equity) 11.6% 10.1% 12.8% 13.1% 9.02% 9.06% 10.4% 10.3%
ROA (Net income/ Total Assets) 8.93% 7.25% 9.28% 9.45% 6.41% 6.9% 8.2% 8.09%
Assets 1 11,317 23,283 36,498 46,798 53,070 56,803 60,819 68,035
Book Value Per Share 2 3.290 5.030 7.300 8.290 9.270 10.70 12.00 13.20
Cash Flow per Share 2 0.3000 0.4400 0.7700 1.270 - 1.580 1.760 1.830
Capex 1 3,211 6,025 6,508 5,868 - 5,306 4,589 3,989
Capex / Sales 80.59% 107.35% 63.24% 38.43% - 29.03% 20.82% 16.35%
Announcement Date 3/26/20 3/23/21 3/22/22 3/22/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
12.91 CNY
Average target price
26.4 CNY
Spread / Average Target
+104.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-53.58% 7.42B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 96.29B
ARGENX SE Stock argenx SE
+1.98% 22.18B
BIONTECH SE Stock BioNTech SE
-16.67% 21.2B
GENMAB A/S Stock Genmab A/S
-9.33% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2269 Stock
  4. Financials WuXi Biologics (Cayman) Inc.